These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 28571738)
1. GPR3 and GPR6, novel molecular targets for cannabidiol. Laun AS; Song ZH Biochem Biophys Res Commun; 2017 Aug; 490(1):17-21. PubMed ID: 28571738 [TBL] [Abstract][Full Text] [Related]
2. GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol. Laun AS; Shrader SH; Brown KJ; Song ZH Acta Pharmacol Sin; 2019 Mar; 40(3):300-308. PubMed ID: 29941868 [TBL] [Abstract][Full Text] [Related]
3. Novel inverse agonists for the orphan G protein-coupled receptor 6. Laun AS; Shrader SH; Song ZH Heliyon; 2018 Nov; 4(11):e00933. PubMed ID: 30480157 [TBL] [Abstract][Full Text] [Related]
4. Discovery of endogenous inverse agonists for G protein-coupled receptor 6. Shrader SH; Song ZH Biochem Biophys Res Commun; 2020 Feb; 522(4):1041-1045. PubMed ID: 31818461 [TBL] [Abstract][Full Text] [Related]
5. Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12. Morales P; Isawi I; Reggio PH Drug Metab Rev; 2018 Feb; 50(1):74-93. PubMed ID: 29390908 [TBL] [Abstract][Full Text] [Related]
6. Cannabidiol, a novel inverse agonist for GPR12. Brown KJ; Laun AS; Song ZH Biochem Biophys Res Commun; 2017 Nov; 493(1):451-454. PubMed ID: 28888984 [TBL] [Abstract][Full Text] [Related]
7. The identification of GPR3 inverse agonist AF64394; the first small molecule inhibitor of GPR3 receptor function. Jensen T; Elster L; Nielsen SM; Poda SB; Loechel F; Volbracht C; Klewe IV; David L; Watson SP Bioorg Med Chem Lett; 2014 Nov; 24(22):5195-8. PubMed ID: 25442311 [TBL] [Abstract][Full Text] [Related]
8. The development of diphenyleneiodonium analogs as GPR3 agonists. Gay EA; Harris DL; Wilson JW; Blough BE Bioorg Med Chem Lett; 2023 Oct; 94():129427. PubMed ID: 37541631 [TBL] [Abstract][Full Text] [Related]
9. Development of a High-Throughput Screening-Compatible Assay for Discovery of GPR3 Inverse Agonists Using a cAMP Biosensor. Ayukawa K; Suzuki C; Ogasawara H; Kinoshita T; Furuno M; Suzuki G SLAS Discov; 2020 Mar; 25(3):287-298. PubMed ID: 31516076 [TBL] [Abstract][Full Text] [Related]
10. Characterization of Four Orphan Receptors (GPR3, GPR6, GPR12 and GPR12L) in Chickens and Ducks and Regulation of Li Z; Jiang B; Cao B; Zhang Z; Zhang J; Li J; Huang Y; Wang Y Genes (Basel); 2021 Mar; 12(4):. PubMed ID: 33801713 [TBL] [Abstract][Full Text] [Related]
11. Identification of a novel small-molecule agonist for human G protein-coupled receptor 3. Ye C; Zhang Z; Wang Z; Hua Q; Zhang R; Xie X J Pharmacol Exp Ther; 2014 Jun; 349(3):437-43. PubMed ID: 24633425 [TBL] [Abstract][Full Text] [Related]
12. Fluid shear stress differentially regulates gpr3, gpr6, and gpr12 expression in human umbilical vein endothelial cells. Uhlenbrock K; Huber J; Ardati A; Busch AE; Kostenis E Cell Physiol Biochem; 2003; 13(2):75-84. PubMed ID: 12649592 [TBL] [Abstract][Full Text] [Related]
13. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease. Patricio F; Morales-Andrade AA; Patricio-Martínez A; Limón ID Front Pharmacol; 2020; 11():595635. PubMed ID: 33384602 [TBL] [Abstract][Full Text] [Related]
14. Methods for the Development of In Silico GPCR Models. Morales P; Hurst DP; Reggio PH Methods Enzymol; 2017; 593():405-448. PubMed ID: 28750813 [TBL] [Abstract][Full Text] [Related]
15. GPR6 Structural Insights: Homology Model Construction and Docking Studies. Isawi IH; Morales P; Sotudeh N; Hurst DP; Lynch DL; Reggio PH Molecules; 2020 Feb; 25(3):. PubMed ID: 32046081 [TBL] [Abstract][Full Text] [Related]
16. Sphingosine 1-phosphate acts as an activator for the porcine Gpr3 of constitutively active G protein-coupled receptors. Zhang BL; Li Y; Ding JH; Dong FL; Hou YJ; Jiang BC; Shi FX; Xu YX J Zhejiang Univ Sci B; 2012 Jul; 13(7):555-66. PubMed ID: 22761247 [TBL] [Abstract][Full Text] [Related]
17. First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate. Sun H; Monenschein H; Schiffer HH; Reichard HA; Kikuchi S; Hopkins M; Macklin TK; Hitchcock S; Adams M; Green J; Brown J; Murphy ST; Kaushal N; Collia DR; Moore S; Ray WJ; English NM; Carlton MBL; Brice NL J Med Chem; 2021 Jul; 64(14):9875-9890. PubMed ID: 33861086 [TBL] [Abstract][Full Text] [Related]
18. Structural basis for the binding of a selective inverse agonist AF64394 with the human G-protein coupled receptor 3 (GPR3). Bharathi ; Roy KK J Biomol Struct Dyn; 2022; 40(20):10181-10190. PubMed ID: 34157950 [TBL] [Abstract][Full Text] [Related]
19. Development of Fluorescent AF64394 Analogues Enables Real-Time Binding Studies for the Orphan Class A GPCR GPR3. Bresinsky M; Shahraki A; Kolb P; Pockes S; Schihada H J Med Chem; 2023 Nov; 66(21):15025-15041. PubMed ID: 37907069 [TBL] [Abstract][Full Text] [Related]
20. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Yamaori S; Okamoto Y; Yamamoto I; Watanabe K Drug Metab Dispos; 2011 Nov; 39(11):2049-56. PubMed ID: 21821735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]